SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-248503
Filing Date
2021-08-17
Accepted
2021-08-17 08:31:07
Documents
15
Period of Report
2021-08-17
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d188133d8k.htm   iXBRL 8-K 26642
2 EX-99.1 d188133dex991.htm EX-99.1 18625
6 GRAPHIC g1881331gra.jpg GRAPHIC 5587
7 GRAPHIC g188133gr2.jpg GRAPHIC 5659
  Complete submission text file 0001193125-21-248503.txt   190773

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20210817.xsd EX-101.SCH 2873
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20210817_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20210817_pre.xml EX-101.PRE 11395
8 EXTRACTED XBRL INSTANCE DOCUMENT d188133d8k_htm.xml XML 3363
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 211181008
SIC: 2836 Biological Products, (No Diagnostic Substances)